Key Points
Sept 26 (Reuters) - The European Union is in talks with Moderna (MRNA.O) over a new supply deal for the company's COVID-19 vaccines amid concerns over a rise in infections in the region, the Financial Times reported on Tuesday, citing two people familiar with the matter...
The company supplied its COVID vaccines to the EU during the pandemic, but the contract for its Omicron-adjusted vaccines ended in August last year and was not renewed...
"Moderna manufactured its updated COVID-19 vaccine at risk to ensure we could support member states with their upcoming vaccination campaigns," a company spokesperson said, adding the updated shot was approved in Europe and ready to be supplied...
The spokesperson said an agreement with the European Commission is the fastest way to procure the shots, which would help ensure a diversified supply of COVID vaccines with vaccination campaigns set to start in October...
A spokesperson for the European Commission declined to comment on the talks over Moderna's supply contract, but added it "has been assessing the needs and interests of the Member States for additional COVID-19 vaccines"...
You might be interested in
EU authorises use of adapted Pfizer/BioNtech vaccine for COVID-19 variant
02, Sep, 23The European Commission has authorised an updated COVID-19 vaccine from Pfizer (PFE.N) and its German partner BioNtech (22UAy.DE) to be used in EU countries' vaccination campaigns this autumn to target the dominant Omicron XBB.1.5 variant, it said on Friday.
Covid vaccines: Why the UK needs to rethink its decision to stop boosters for young and healthy people
18, Feb, 23The UK Joint Committee on Vaccination and Immunisation (JCVI) recently recommended that the current autumn booster campaign, offering additional COVID vaccine doses to higher-risk groups, including people with certain medical conditions and those aged over 50, will end on February 12.
Novavax: The new FDA-approved COVID-19 vaccine with fewer side effects
05, Oct, 23The FDA approved an updated COVID-19 vaccine from Novavax. The vaccine is more effective at protecting against omicron strains of the virus.
Meesho posts maiden profit in July, weighs IPO in 12-18 months
08, Aug, 23The startup expects to close the current financial year with 40% growth in revenue run rate
Novavax exec says its new COVID shot should work against variants on the rise
06, Jun, 23Novavax Inc's head of research and development on Monday said an updated COVID-19 vaccine the company is already producing is likely to be protective against other fast-growing coronavirus variants circulating in the U.S.
FDA Approves New Covid Vaccines Amid Summer Surge
26, Aug, 24The updated vaccines target the currently circulating KP.2 variant.
Exclusive: EU to announce deal with Pfizer, others to reserve vaccines for future pandemic
30, Jun, 23The European Commission has contracted pharma companies including Pfizer to reserve capacity to make up to 325 million vaccines per year in case of a future global health emergency, a source familiar with the matter told Reuters.
'Be alert for next 10-15 days,' Maharashtra minister says ahead of New Year
30, Dec, 23Maharashtra records 129 Covid cases, while India reports 162 cases of Covid-19 subvariant JN.1
Moderna, Pfizer hit with new patent lawsuits over COVID vaccines
07, Jun, 23Biotech firm Promosome LLC sued Moderna , Pfizer and BioNTech , in federal court in San Diego, California, on Tuesday, accusing their COVID-19 vaccines of infringing a patent related to messenger RNA technology.
Explained: Why AstraZeneca has decided to withdraw its Covid vaccine globally
08, May, 24AstraZeneca had recently admitted in court documents that its vaccine against Covid-19 has the potential to cause TTS, a rare side effect associated with blood clotting.